By VETTAPHARMA reporter – Derek Roche: Daiichi Sankyo reported that it will present more than 25 abstracts across its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting new clinical analyses from landmark Enhertu and Datroway studies alongside early-stage pipeline programs developed through its breakthrough generating technology platform. The company’s ASCO presentations include new analyses from five major trials: DESTINY-Breast05, DESTINY-Breast06, DESTINY-Breast09, DESTINY-Gastric04, and TROPION-Breast02. The datasets build on recent regulatory momentum for both Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), which recently secured new approvals in breast and gastric cancer settings.
Data from DESTINY-Breast05 contributed to one of two recently approved U.S. indications for Enhertu in early-stage HER2-positive breast cancer, while DESTINY-Gastric04 supported label expansion in Japan and China for second-line HER2-positive metastatic gastric cancer. Results from TROPION-Breast02 formed the basis of Datroway’s recent U.S. approval in metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy.
Among the featured presentations, Daiichi Sankyo will present updated analyses from DESTINY-Breast09 evaluating treatment duration and clinical outcomes with trastuzumab deruxtecan plus pertuzumab, as well as safety findings from DESTINY-Breast05 examining interstitial lung disease and radiation pneumonitis risk factors. Additional breast cancer presentations include final analyses from DESTINY-Breast07 evaluating trastuzumab deruxtecan plus durvalumab in first-line HER2-positive metastatic breast cancer.
The ASCO program also expands beyond breast cancer into gastric, ovarian, urothelial, salivary gland, acute myeloid leukemia, and pan-tumor studies. New data include results from DESTINY-Ovarian01 evaluating trastuzumab deruxtecan plus bevacizumab in HER2-expressing ovarian cancer, MYTHOS evaluating trastuzumab deruxtecan in HER2-low salivary gland carcinoma, and studies exploring HER2-directed therapies across multiple solid tumors.
Daiichi Sankyo will additionally showcase development programs involving several next-generation antibody-drug conjugates, including raludotatug deruxtecan, patritumab deruxtecan, and ifinatamab deruxtecan. Multiple trials-in-progress presentations will evaluate these assets in platinum-resistant ovarian cancer, metastatic breast cancer, urothelial carcinoma, and other advanced solid tumors.
The company also highlighted three early-stage investigational medicines developed through its breakthrough generating technology platform: DS3610, a STING agonist antibody-drug conjugate; DS5361, a nonsense-mediated mRNA decay inhibitor; and DS9051, a targeted protein degradation molecule. All three candidates are currently being evaluated in first-in-human studies involving advanced or metastatic cancers.
The ASCO presentations reinforce Daiichi Sankyo’s strategy of expanding its oncology leadership through a broad antibody-drug conjugate portfolio spanning both commercial-stage products and next-generation pipeline assets. With multiple late-stage studies supporting recent approvals and additional development programs advancing across solid tumors and hematologic malignancies, the company continues to strengthen its position within the increasingly competitive ADC market.
For patients, the research program may support expanded treatment options across multiple difficult-to-treat cancers, particularly in HER2-expressing tumors and advanced disease settings where unmet medical needs remain substantial.
Quick FAQs
1. What did Daiichi Sankyo announce at ASCO 2026?
Daiichi Sankyo announced more than 25 oncology abstracts featuring clinical updates across its ADC portfolio and early-stage cancer pipeline.
2. Which medicines are being highlighted?
Key programs include Enhertu, Datroway, raludotatug deruxtecan, patritumab deruxtecan, ifinatamab deruxtecan, and several early-stage oncology candidates.
3. What is the study/trial?
The ASCO program includes data from DESTINY-Breast05, DESTINY-Breast06, DESTINY-Breast09, DESTINY-Gastric04, TROPION-Breast02, DESTINY-Ovarian01, MYTHOS, and several additional oncology studies.
4. What is the disease condition?
The studies span multiple cancers including breast, gastric, ovarian, urothelial, salivary gland, acute myeloid leukemia, and other advanced solid tumors.
5. Why are the ASCO presentations important?
Several datasets support recently approved indications while additional studies may expand future treatment opportunities across oncology settings.
6. What is Daiichi Sankyo’s broader oncology strategy?
The company is expanding an industry-leading antibody-drug conjugate portfolio while advancing new breakthrough-generating technologies targeting multiple cancer types.
